Newsroom

Displaying 1–10 of 135

July 8, 2026

Seer Board of Directors Issues Letter to Shareholders Demonstrating the Strength and Experience of Seer’s Director Nominees

July 6, 2026

Seer Files Investor Presentation Highlighting Strong Momentum, Commercial Opportunity and Significant Long-Term Value Creation Potential

July 2, 2026

Seer Announces Receipt of Unsolicited Acquisition Proposal from Omid Farokhzad, M.D.

July 1, 2026

Seer Prevails in European Patent Opposition as U.S. ITC Opens Investigation into Nanomics

June 22, 2026

Seer and Korea University Present Preliminary Data at ASMS 2026 Demonstrating Potential of AI-Driven Plasma Proteomics for Multi-Cancer Screening

June 15, 2026

Seer Board of Directors Issues Letter to Shareholders Highlighting the Company’s Significant Scientific Progress and Addressing Radoff and Torok’s Short-Sighted Campaign

June 3, 2026

Seer Files Definitive Proxy Materials and Mails Letter to Stockholders

May 29, 2026

Seer Files ITC Complaint Against Nanomics

May 26, 2026

Seer to Showcase AI-Driven Multi-Cancer Screening Approach and Next-Generation Proteomics Capabilities at ASMS 2026

May 21, 2026

Seer Board of Directors Unanimously Rejects Further Revised Unsolicited Proposal from Radoff-JEC Group

Starting your proteomics research is effortless

Connect with an expert to discuss which path to the full proteome is right for you.

  1. Bring the Proteograph Product Suite in-house
  2. Run a project with
    Seer Technology
    Access Center
  3. Conduct a project with
    a Seer service provider
    or Center of Excellence